The use of cilostazol for secondary stroke prevention: isn’t it time it’s evaluated in Western countries?

Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review

“…We also found that monotherapies with aspirin or ticagrelor and DAPT with aspirin and clopidogrel are mainly used in western Europe and the USA, while cilostazol, either alone or combined with aspirin, is predominantly used in Asia [cf. (34)]. However, the experts assume that there is no reason to test cilostazol in Europe and the USA since it has a good safety profile and seems safer than aspirin and is probably safer than other antithrombotic drugs in terms of reducing bleeding complications, especially hemorrhagic strokes.…”

Cilostazol-imprinted polymer film-coated electrode as an electrochemical chemosensor for selective determination of cilostazol and its active primary metabolite

“…Moreover, CIL is considered to treat diseases like Alzheimer's disease (AD), 6 diabetes, 7 strokes, 8 and hypertension. 9 Currently, CIL is undergoing several clinical trials.…”

“…Two of these, namely, 3,4-dehydrocilostazol (dhCIL) (Scheme 1) and monohydroxycilostazol (not shown), are also responsible for inhibitory effects on platelet aggregation. 5 Moreover, CIL is considered to treat diseases like Alzheimer's disease (AD), 6 diabetes, 7 strokes, 8 and hypertension. 9 Currently, CIL is undergoing several clinical trials.…”